Generation of Polyclonal CMV-specific T Cells for the Adoptive Immunotherapy of Glioblastoma

• DOI: 10.1097/cji.0b013e318247642f
• Publication Date: 2012-02-01T11:07:16Z
• Authors: Alexia Ghazi; Aidin Ashoori; Patrick J. Hanley; Vita S. Brawley; Donald R. Shaffer; Yvonne Kew; Suzanne Z. Powell; Robert Grossman; Zakaria Grada; Michael E. Scheurer; Meenakshi Hegde; Ann M. Leen; Catherine M. Bollard; Cliona M. Rooney; Helen E. Heslop; Stephen Gottschalk; Nabil Ahmed
• Keywords: Polyclonal antibodies; ELISPOT; Cytomegalovirus

Glioblastoma (GBM) is the most common primary brain cancer in adults and virtually incurable. Recent studies have shown that cytomegalovirus (CMV) present majority of GBMs. To evaluate whether CMV antigens pp65 IE1, which are expressed GBMs, could be targeted by CMV-specific T cells, we measured frequency cells targeting IE1 peripheral blood a cohort 11 sequentially diagnosed CMV-seropositive GBM patients, evaluated it was feasible to expand autologous for future clinical studies. All patients had specific their assessed IFNγ enzyme-linked immunospot assay. However, precursor pp65-specific decreased comparison with healthy donors (P=0.001). We successfully reactivated expanded from 6 out using antigen-presenting transduced an adenoviral vector encoding IE1. T-cell lines contained CD4+ as well CD8+ recognized pp65+ IE1+ targets killed CMV-infected cells. Infusion such may extend benefits therapy CMV+